A study recently published in the journal Oncogene revealed a new therapeutic strategy for advanced metastatic melanoma based on the interaction between two particular factors – Pin1 and FOXM1. The study is entitled “Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling”, and was led by researchers at the University Medical Center Utrecht and the Erasmus Medical Center Rotterdam in The Netherlands, and The Buck Institute for Research on Aging in the United States.
MRV Research
FDA grants priority review to Keytruda for first-line treatment of advanced melanoma
The FDA granted priority review to pembrolizumab for the first-line treatment of patients with unresectable or metastatic melanoma, according to a press release from the drug’s manufacturer.
Immunosuppression, older age linked to higher risk for aggressive melanoma
Researchers found that older patients and patients with immunosuppression are at higher risk for aggressive melanoma, according to recent research.
Frontline Pembrolizumab Receives FDA Priority Review in Melanoma
The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma, according to Merck, the manufacturer of the anti–PD-1 therapy. A final decision is scheduled from the FDA by December 19, 2015.